Standard BioTools

Standard BioTools Change in Working Capital

The Change in Working Capital of Standard BioTools (LAB) as of Nov 5, 2026 is -44.98 M USD. In the previous year, Change in Working Capital was -12.08 M USD — a change of 272.37% (lower).

Change in Working Capital

-44.98 MUSD

YoY

272.37%

Last updated:

Change in Working Capital of Standard BioTools is 2025 -44.98 M USD. Change in Working Capital of Standard BioTools was 2024 -12.08 M USD. It decreases by 272.37% lower compared to the previous year.

The Standard BioTools Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
-2.48 M USD
Jan 1, 2019
-16.51 M USD
Jan 1, 2020
2.41 M USD
Jan 1, 2021
-18.01 M USD
Jan 1, 2022
-12.35 M USD
Jan 1, 2023
1.79 M USD
Jan 1, 2024
-12.08 M USD
Jan 1, 2025
-44.98 M USD
The Standard BioTools Change in Working Capital history
YEARChange in Working CapitalYoY
-44.98 MUSD+272.37%
-12.08 MUSD-775.94%
1.79 MUSD-114.47%
-12.35 MUSD-31.40%
-18.01 MUSD-845.90%
2.41 MUSD-114.62%
-16.51 MUSD+566.38%
-2.48 MUSD-126.92%
9.20 MUSD+93.69%
4.75 MUSD-157.71%
-8.23 MUSD+4.91%
-7.85 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Change in Working Capital of Standard BioTools is -44.98 M USD in 2025.

Change in Working Capital of Standard BioTools changed from -12.08 M USD to -44.98 M USD, representing a 272.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Standard BioTools

All Key Metrics — Standard BioTools